CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Gilead Sciences, Inc. v. Mylan Pharmaceuticals Inc.

1:17-cv-00187

Overview

Case Number 1:17-cv-00187
Filing Date 2017-02-22
Status Terminated
Termination Date 2018-07-24
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

Mylan Pharmaceuticals Inc. Operating Company

Represented By

1 Attorneys Listed

James Michael Lennon

Devlin Law Firm

Tel: +1 (302) 449-9010
Fax: +1 (302) 353-4251

1526 Gilpin Avenue, 19806

Plaintiff

Gilead Sciences, Inc. Operating Company

Represented By

7 Attorneys Listed

Rebecca T. Horwitz

Email: rebecca.horwitz@bartlitbeck.com

Nevin M. Gewertz

Email: nevin.gewertz@bartlitbeck.com

John S. McBride

Email: scott.mcbride@bartlit-beck.com

Jeremy A. Tigan

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 351-9106

1201 North Market Street, P.O. Box 1347

James B. Heaton , III

UNDELIVERABLE EMAIL 4/30/2018

Adam K. Mortara

Email: adam@mortaralaw.com

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 8 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (8): πŸ‡ΊπŸ‡Έ US
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

1 Patent

There is a single patent involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US8148374
Modulators of pharmacokinetic properties of therapeutics
Filed: 2008-02-22
Issued: 2012-04-03
Active (2.8 yrs remaining) +559d PTA
Expires: 2029-09-03

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Active Threat

Active Threat β€” Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+559 days) / Cellect Scrutiny β€” Over 559 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

2

Dispositive

0

Granted

0

Denied

0

Pending / Review

1

Motions by Category

Procedural / Extension Motion 2

Key Dispositive Motions & Rulings

Procedural / Extension Motion Pending
SO ORDERED, re 7 STIPULATION TO EXTEND TIME for Defendant to answer, move, or otherwise respond to Complaint to March 23, 2017 (*Reset Answer Deadlines: Mylan P...
Entry #β€” • 2017-03-16
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME for Defendant to answer, move, or otherwise respond to Complaint to March 23, 2017 - filed by Mylan Pharmaceuticals Inc.. (Lennon, Ja...
Entry #7 • 2017-03-15 Document →

Docket Entries

(34 total)
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed against Mylan Pharmaceuticals Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2089549.) - filed by Gilead Sciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Civil Cover Sheet)(jcs) (Entered: 02/22/2017)

Entry #1 • 2017-02-22
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (jcs) (Entered: 02/22/2017)

Entry #2 • 2017-02-22
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: January 25, 2017. Date of Expiration of Patent: September 3, 2029. Thirty Month Stay Deadline: 7/25/2019. (jcs) Modified on 6/22/2017 (nms). (Entered: 02/22/2017)

Entry #3 • 2017-02-22
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,148,374 B2. (jcs) (Entered: 02/22/2017)

Entry #4 • 2017-02-22
1

Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Gilead Sciences, Inc. (jcs) (Entered: 02/22/2017)

Entry #5 • 2017-02-22
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc